Every 8-K that Collegium Pharmaceutical, Inc. (COLL) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow COLL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full COLL filings page.
Collegium Pharmaceutical, Inc. entered into an accelerated share repurchase (ASR) agreement with Jefferies LLC to repurchase $50 million of its common stock. This transaction is part of a previously authorized $150 million share repurchase program approved in July 2025.
Collegium will pay $50 million to Jefferies and receive an initial delivery of 1,556,420 shares, calculated using the $25.70 closing stock price on August 12, 2026. This initial delivery represents approximately 80% of the total shares expected to be repurchased under the ASR. The final number of shares will be determined based on the volume-weighted average price of Collegium’s common stock during the ASR period, with final settlement expected no later than the fourth quarter of 2026. As of June 30, 2026, Collegium had approximately 32.5 million shares outstanding.
Collegium Pharmaceutical reported Q2 2026 results with product revenues, net of $199.9 million, up 6% year-over-year, driven by its ADHD and pain portfolios. JORNAY PM net revenue reached $46.1 million, up 41%, and newly acquired AZSTARYS contributed $12.9 million from a partial quarter.
Profitability metrics remained strong on an adjusted basis. Despite a GAAP net loss of $15.1 million, or $0.46 per share, non-GAAP adjusted net income was $75.4 million with adjusted earnings per share of $1.92. Adjusted EBITDA rose to $113.8 million, up 8%, and operating cash flow was $71.3 million, ending the quarter with $129.5 million in cash and cash equivalents.
Guidance for 2026 was updated. Product revenues, net are now expected between $825 million and $855 million and adjusted EBITDA between $445 million and $470 million, reflecting lower-than-expected authorized generic Nucynta pricing, while JORNAY PM guidance is unchanged and AZSTARYS revenue guidance increased to $65–$75 million.
Collegium Pharmaceutical, Inc. filed an amended Form 8-K to provide detailed historical and pro forma financial information related to its acquisition of AZSTARYS. Collegium completed the purchase of interests in GPC Commave Holding, LLC and Commave Sub, LLC, gaining AZSTARYS, an ADHD treatment for patients 6 and older.
The aggregate cash consideration at closing was approximately $655.6 million, funded by about $355.6 million of existing cash and $300.0 million from a delayed draw term loan under its 2025 credit agreement. Collegium may pay up to an additional $135 million to Commave Seller upon achieving specified future AZSTARYS commercial and manufacturing milestones.
The amendment adds audited and unaudited consolidated financial statements of Corium Therapeutics Holdings, LLC and unaudited pro forma condensed combined financial statements of Collegium. Corium’s consolidated statements include both AZSTARYS and ADLARITY, but ADLARITY was not acquired and is excluded from the pro forma information, which reflects AZSTARYS only. Corium’s auditors highlighted recurring losses, net capital deficiency, and substantial doubt about Corium’s ability to continue as a going concern before the acquisition.
Collegium Pharmaceutical, Inc. reported results of its 2026 Annual Meeting of Shareholders. A total of 32,406,969 common shares were entitled to vote as of March 31, 2026, and 29,210,926 shares were represented in person or by proxy.
Shareholders elected eight directors, including Rita Balice-Gordon and Garen Bohlin, to serve until the 2027 Annual Meeting. On an advisory basis, shareholders approved the compensation of the company’s named executive officers. Shareholders also ratified Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
Collegium Pharmaceutical completed its acquisition of AZSTARYS, a CNS stimulant for ADHD, for approximately $650 million in cash, funded with about $350 million of existing cash and a $300 million delayed draw term loan. The deal also includes up to $135 million in milestone payments. Collegium raised its 2026 guidance, now expecting total product revenues, net of $865 to $895 million and adjusted EBITDA of $475 to $500 million, including expected AZSTARYS net revenue of $60 to $70 million for the remainder of 2026 and annual run rate synergies expected to exceed $50 million within twelve months. AZSTARYS generated more than 760,000 prescriptions in 2025 and is supported by six Orange Book-listed patents, most expiring in December 2037. The company also adopted a 2026 Inducement Plan covering up to 325,000 shares for new hires and announced upcoming departures of its Chief Commercial Officer and Chief Medical Officer, both treated as terminations without cause with transition periods.
Collegium Pharmaceutical reported strong first quarter 2026 results and reiterated its full-year outlook. Product revenues, net were $193.5 million, up 9% year-over-year, driven by ADHD drug JORNAY PM net revenue of $38.9 million, up 36%, and pain portfolio revenue of $154.6 million, up 4%.
GAAP net income rose to $14.5 million, while non-GAAP adjusted net income reached $69.2 million and adjusted EBITDA was $103.9 million, both up 9% year-over-year. The company ended the quarter with $421.8 million in cash, cash equivalents and marketable securities and generated $57.1 million in operating cash flow.
Collegium reaffirmed 2026 guidance for product revenues, net of $805–$825 million, JORNAY PM revenue of $190–$200 million, and adjusted EBITDA of $455–$475 million, excluding the planned acquisition of ADHD medicine AZSTARYS. The AZSTARYS deal totals $650 million in cash plus up to $135 million in milestones and is expected to be immediately accretive to adjusted EBITDA after an anticipated close in the second quarter of 2026.
Collegium Pharmaceutical, Inc. announced changes to its board of directors. The board approved the nomination of Michael Donovan, 60, an audit Partner at Ernst & Young LLP since 2002, to stand for election at the 2026 Annual Meeting of Shareholders.
The company also disclosed that John Fallon, M.D., a director since 2016, will not stand for re-election and will retire from the board at the Annual Meeting. His decision is described as part of ongoing board refreshment and succession planning and not due to any disagreement with the company.
Collegium Pharmaceutical plans to acquire AZSTARYS, an ADHD medicine, for $650 million in cash, plus up to $135 million in potential regulatory and commercial milestone payments. The deal will give Collegium full ownership of entities holding AZSTARYS and is expected to close in the second quarter of 2026, subject to customary conditions including Hart-Scott-Rodino clearance.
The transaction is funded by about $350 million of cash on hand and a previously announced $300 million delayed draw term loan, with net debt to adjusted EBITDA projected around 2x at closing. Collegium expects AZSTARYS to generate more than $50 million of pro forma net revenue in the second half of 2026, deliver over $50 million in annual run-rate synergies within 12 months of close, and be immediately accretive to adjusted EBITDA. Patent protection for AZSTARYS is expected to extend into 2037, strengthening Collegium’s ADHD franchise alongside JORNAY PM and further diversifying revenue beyond its pain portfolio.
Collegium Pharmaceutical reported strong fourth-quarter and full-year 2025 results, led by its ADHD drug Jornay PM and its pain portfolio. Q4 2025 product revenues, net were $205.4 million, up 13% year-over-year, and adjusted EBITDA reached $127.3 million, up 18%.
For full-year 2025, product revenues, net grew to $780.6 million from $631.4 million, a 24% increase, while adjusted EBITDA rose to $460.5 million, up 15%. Jornay PM net revenue was $148.9 million, up 48%, and the pain portfolio delivered $631.7 million, up 6%.
GAAP net income for 2025 was $62.9 million (diluted EPS $1.73), down from $69.2 million in 2024, while non-GAAP adjusted net income increased to $289.3 million (adjusted EPS $7.42). The company generated $329.3 million in cash from operations and ended 2025 with $386.7 million in cash, cash equivalents and marketable securities. A new $980 million syndicated credit facility refinanced prior debt and is expected to lower interest costs. Collegium reaffirmed its 2026 guidance, including product revenues, net of $805–$825 million and adjusted EBITDA of $455–$475 million.
Collegium Pharmaceutical, Inc. reported that it has issued full-year 2026 guidance for revenue and adjusted EBITDA. The company disclosed this information in a press release that is furnished as an exhibit and not filed for liability purposes. It also posted a corporate presentation on its website that may be used in discussions with investors, analysts and other stakeholders, and furnished that presentation as a separate exhibit.
The company emphasized that these outlook figures and related commentary are forward-looking statements based on current management expectations and are subject to numerous risks and uncertainties. It highlighted factors such as commercialization performance of its products, market size and acceptance, reimbursement, regulatory developments, litigation, supply, financing needs and intellectual property protection as key risks that could cause actual results to differ materially from the guidance.
Collegium Pharmaceutical (COLL) reported that it released its financial results for the quarter ended September 30, 2025. The company furnished a press release and an earnings presentation alongside this update.
The materials were provided as exhibits to an 8-K: Exhibit 99.1 (press release) and Exhibit 99.2 (earnings presentation). Both exhibits were furnished under Items 2.02 and 7.01. COLL’s common stock trades on the NASDAQ Global Select Market.
Collegium Pharmaceutical, Inc. (NASDAQ: COLL) disclosed in an 8-K filed on July 1, 2025 that its Board authorized a new share repurchase program of up to $150 million of common stock, effective immediately and running through December 31, 2026.
The company intends to execute buybacks on the open market at management’s discretion, considering prevailing market conditions and share price. Funding will come exclusively from existing cash on hand; no additional debt or equity issuance is mentioned. The filing contains no earnings figures, operational updates, or changes to prior guidance.
While the authorization does not obligate the company to repurchase the full amount, the program could reduce the share count, provide support for the stock price, and signal management’s confidence in long-term prospects. Investors should note that the timing, pace, and ultimate utilization of the $150 million limit remain subject to market dynamics and internal capital allocation priorities.